{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:58:33Z","timestamp":1768474713681,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00403-019-01981-2","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:53:50Z","timestamp":1572468830000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop\u2122 for psoriasis"],"prefix":"10.1007","volume":"312","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-7882","authenticated-orcid":false,"given":"Kendice","family":"Ip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiyun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Banov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"August S.","family":"Bassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benigno C.","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"1981_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","volume":"47","author":"CG Helmick","year":"2014","unstructured":"Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL (2014) Prevalence of psoriasis among adults in the U.S.: 2003\u20132006 and 2009\u20132010 National Health and Nutrition Examination Surveys. Am J Prev Med. 47:37\u201345","journal-title":"Am J Prev Med."},{"key":"1981_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496\u2013509","journal-title":"N Engl J Med"},{"key":"1981_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/1523-1747.ep12283594","volume":"85","author":"GD Weinstein","year":"1985","unstructured":"Weinstein GD, McCullough JL, Ross PA (1985) Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol. 85:579\u2013583","journal-title":"J Invest Dermatol."},{"key":"1981_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2133.1985.tb02044.x","volume":"113","author":"IM Leigh","year":"1985","unstructured":"Leigh IM, Pulford KA, Ramaekers FC, Lane EB (1985) Psoriasis: maintenance of an intact monolayer basal cell differentiation compartment in spite of hyperproliferation. Br J Dermatol 113:53\u201364","journal-title":"Br J Dermatol"},{"key":"1981_CR5","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.biocel.2008.10.022","volume":"41","author":"G Tonel","year":"2009","unstructured":"Tonel G, Conrad C (2009) Interplay between keratinocytes and immune cells\u2013recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 41:963\u2013968","journal-title":"Int J Biochem Cell Biol"},{"key":"1981_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227\u2013255","journal-title":"Annu Rev Immunol"},{"key":"1981_CR7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R (2018) Pathogenesis of psoriasis and development of treatment. J Dermatol 45:264\u2013272","journal-title":"J Dermatol"},{"key":"1981_CR8","first-page":"12","volume":"18","author":"YR Woo","year":"2017","unstructured":"Woo YR, Cho DH, Park HJ (2017) Molecular mechanisms and management of a cutaneous inflammatory disorder: psoriasis. Int J Mol Sci 18:12","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1981_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"C Conrad","year":"2018","unstructured":"Conrad C, Gilliet M (2018) Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol 54(1):102\u2013113","journal-title":"Clin Rev Allergy Immunol"},{"key":"1981_CR10","volume-title":"Martindale: the complete drug reference","author":"SC Sweetman","year":"2007","unstructured":"Sweetman SC (2007) Martindale: the complete drug reference, 35th edn. Pharmaceutical Press, New York","edition":"35"},{"key":"1981_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","volume":"63","author":"NQ Phan","year":"2010","unstructured":"Phan NQ, Bernhard JD, Luger TA, Stander S (2010) Antipruritic treatment with systemic mu-opioid receptor antagonists: a review. J Am Acad Dermatol 63:680\u2013688","journal-title":"J Am Acad Dermatol"},{"key":"1981_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"J Younger","year":"2014","unstructured":"Younger J, Parkitny L, McLain D (2014) The use of low-dose naltrexone [LDN] as a novel anti-inflammatory treatment for chronic pain\u2019. Clin Rheum. 33:451\u2013459","journal-title":"Clin Rheum."},{"key":"1981_CR13","unstructured":"Low Dose Naltrexone [LDN] and Autoimmune Disease. \nhttps:\/\/www.lowdosenaltrexone.org\/ldn_and_ai.htm\n\n. Accessed 28 Dec 2018"},{"key":"1981_CR14","first-page":"1140","volume":"16","author":"L Strazzulla","year":"2017","unstructured":"Strazzulla L, Avila L, Lo Sicco K, Shapiro J (2017) Novel treatment using low-dose naltrexone for lichen planopilaris. J Drugs Dermatol 16:1140\u20131142","journal-title":"J Drugs Dermatol"},{"key":"1981_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jdcr.2018.06.001","volume":"4","author":"AC Bridgman","year":"2018","unstructured":"Bridgman AC, Kirchhof MG (2018) Treatment of psoriasis vulgaris using low-dose naltrexone. JAAD Case Rep. 4:827\u2013829","journal-title":"JAAD Case Rep."},{"key":"1981_CR16","unstructured":"Professional Compounding Centers of America. XemaTop\u2122. [PCCA Website]. \nhttp:\/\/www.pccarx.com\/compounding-for-winter-conditions"},{"key":"1981_CR17","first-page":"205","volume":"21","author":"N Jones","year":"2017","unstructured":"Jones N, Carvalho M, Branvold-Herr A (2017) Management of psoriasis with a XemaTop topical compounded formula: a case report. Int J Pharm Compd 21:205\u2013211","journal-title":"Int J Pharm Compd"},{"key":"1981_CR18","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2005). \u2018Validation of Analytical Procedures: Text and Methodology Q2 [R1]\u2019. Quality Guidelines. \nhttp:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf"},{"key":"1981_CR19","unstructured":"The United States Pharmacopeial Convention (2018) \u2018General Chapters\/<1225> Validation of Compendial Procedures\u2019. USP 40\u2014NF 35 S2. Rockville: USP, pp 8094\u20138099"},{"key":"1981_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS (2011) Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med [Maywood]. 236:1036\u20131050","journal-title":"Exp Biol Med [Maywood]."},{"key":"1981_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12865-015-0093-0","volume":"16","author":"PJ McLaughlin","year":"2015","unstructured":"McLaughlin PJ, McHugh DP, Magister MJ, Zagon IS (2015) Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis. BMC Immunol. 16:24","journal-title":"BMC Immunol."},{"key":"1981_CR22","first-page":"199","volume":"1","author":"J Gerdes","year":"1990","unstructured":"Gerdes J (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1:199\u2013206","journal-title":"Semin Cancer Biol"},{"key":"1981_CR23","first-page":"4043","volume":"17","author":"W Wang","year":"2018","unstructured":"Wang W, Yu X, Wu C, Jin H (2018) Differential effects of Wnt5a on the proliferation, differentiation and inflammatory response of keratinocytes. Mol Med Rep. 17:4043\u20134048","journal-title":"Mol Med Rep."},{"key":"1981_CR24","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1159\/000430158","volume":"36","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Tu C, Zhang D, Zheng Y, Peng Z, Feng Y, Xiao S, Li Z (2015) Wnt\/\u03b2-Catenin and Wnt5a\/Ca pathways regulate proliferation and apoptosis of keratinocytes in psoriasis lesions. Cell Physiol Biochem 36:1890\u20131902","journal-title":"Cell Physiol Biochem"},{"key":"1981_CR25","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1242\/jcs.00623","volume":"116","author":"Y Kawano","year":"2003","unstructured":"Kawano Y, Kypta R (2003) Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627\u20132634","journal-title":"J Cell Sci"},{"key":"1981_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00403-018-1879-8","volume":"5","author":"M Zhang","year":"2018","unstructured":"Zhang M, Zhang X (2018) The role of PI3K\/AKT\/FOXO signaling in psoriasis. Arch Dermatol Res 5:16. \nhttps:\/\/doi.org\/10.1007\/s00403-018-1879-8\n\n(Epub ahead of print)","journal-title":"Arch Dermatol Res"},{"key":"1981_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12964-018-0271-9","volume":"16","author":"Y Wu","year":"2018","unstructured":"Wu Y, Liu L, Bian C, Diao Q, Nisar MF, Jiang X, Bartsch JW, Zhong M, Hu X, Zhong JL (2018) MicroRNA let-7b inhibits keratinocyte differentiation by targeting IL-6 mediated ERK signaling in psoriasis. Cell Commun Signal. 16:58","journal-title":"Cell Commun Signal."},{"key":"1981_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"J Younger","year":"2014","unstructured":"Younger J, Parkitny L, McLain D (2014) The use of low-dose naltrexone [LDN] as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33:451\u2013459","journal-title":"Clin Rheumatol"},{"key":"1981_CR29","doi-asserted-by":"publisher","first-page":"e0188607","DOI":"10.1371\/journal.pone.0188607","volume":"12","author":"C Leong","year":"2017","unstructured":"Leong C, Neumann C, Ramasamy S, Rout B, Yi Wee L, Bigliardi-Qi M, Bigliardi PL (2017) Investigating endogenous \u00b5-opioid receptors in human keratinocytes as pharmacological targets using novel fluorescent ligand. PLoS One 12:e0188607","journal-title":"PLoS One"},{"key":"1981_CR30","doi-asserted-by":"publisher","first-page":"e91577","DOI":"10.1371\/journal.pone.0091577","volume":"9","author":"FE Lennon","year":"2014","unstructured":"Lennon FE, Mirzapolazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA (2014) The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition [EMT] in human lung cancer. PLoS One 9:e91577","journal-title":"PLoS One"},{"key":"1981_CR31","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3389\/fimmu.2018.02786","volume":"9","author":"C Buerger","year":"2018","unstructured":"Buerger C (2018) Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target. Front Immunol 9:2786","journal-title":"Front Immunol"},{"key":"1981_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/ars.2016.6769","volume":"26","author":"JC Chamcheu","year":"2017","unstructured":"Chamcheu JC, Adhami VM, Esnault S, Sechi M, Siddiqui IA, Satyshur KA, Syed DN, Dodwad SM, Chaves-Rodriquez MI, Longley BJ, Wood GS, Mukhtar H (2017) Dual inhibition of PI3\u00a0K\/Akt and mTOR by the dietary antioxidant, delphinidin, ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like disease in mice. Antioxid Redox Signal 26:49\u201369","journal-title":"Antioxid Redox Signal"},{"key":"1981_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neuroscience.2010.08.064","volume":"171","author":"Y Cui","year":"2010","unstructured":"Cui Y, Zhang XQ, Cui Y, Xin WJ, Jing J, Liu XG (2010) Activation of phosphatidylinositol 3-kinase\/Akt-mammalian target of Rapamycin signaling pathway in the hippocampus is essential for the acquisition of morphine-induced place preference in rats. Neuroscience. 171:134\u2013143","journal-title":"Neuroscience."},{"key":"1981_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000237257","volume":"109","author":"P Paquet","year":"1996","unstructured":"Paquet P, Pierard GE (1996) Interleukin-6 and the skin. Intl Arch Allergy Immun. 109:308\u2013317","journal-title":"Intl Arch Allergy Immun."},{"key":"1981_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/11311020-000000000-00000","volume":"10","author":"SR Feldman","year":"2009","unstructured":"Feldman SR, Yentzer BA (2009) Topical clobetasol propionate in the treatment of psoriasis. Am J Clin Dermatol 10:397\u2013406","journal-title":"Am J Clin Dermatol"},{"key":"1981_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2229-5178.209622","volume":"8","author":"R Torsekar","year":"2017","unstructured":"Torsekar R, Gautam MM (2017) Topical therapies in psoriasis. Indian Dermatol Online J. 8:235\u2013245","journal-title":"Indian Dermatol Online J."},{"issue":"1","key":"1981_CR37","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-018-8668-1","volume":"54","author":"C Conrad","year":"2018","unstructured":"Conrad C, Gilliet M (2018) Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol 54(1):102\u2013113","journal-title":"Clin Rev Allergy Immunol"},{"key":"1981_CR38","unstructured":"The United States Pharmacopeial Convention (2018) \u2018General Chapters\/<1191> Stability Considerations in Dispensing Practice\u2019. USP 40\u2014NF 35 S2. Rockville: USP, pp 1662\u20131667"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-019-01981-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01981-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:23:44Z","timestamp":1603931024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-019-01981-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1981"],"URL":"https:\/\/doi.org\/10.1007\/s00403-019-01981-2","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors Kendice Ip, Guiyun Song, Daniel Banov and August S. Bassani are full-time employees of PCCA, the manufacturer of the proprietary base XemaTop\u2122.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}